BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Net Income

Bottom-line profit after all expenses, interest, and taxes.

BioNTech SENASDAQ: BNTX

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income remains negative

Q2 FY2026 net income was -€820.8M, compared with -€386.6M a year earlier. Trailing-twelve-month net income was -€1.69B.

Context

  • Net income amounted to 39.6% of revenue in FY2025, up 15.4 pp from a year earlier.
  • Net income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 11 analysts of -€1.37B (-26.0%) for the fiscal year ending Dec 2026, a step up from the -64.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-€820.8M-51.8% QoQ
Last fiscal yearDec 2025
-€1.09B-64.0% YoY
LTMJun 2026
-€1.69B-390.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-112.3%+697.5%+809.8 pp
1 year-64.0%-26.0%+38.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the income statement

Latest · FY2025
(1.09B) EUR
Year-over-year change
-64.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -390.8% is the 9th highest of 10, against a peer median of +8.8%.
  • Net income amounts to 64.0% of revenue for BNTX, versus a peer median of 46.4%.
BNTX Competitors
Net Income for BNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.61B USD+85.1%+55.7%27.7%
GMABGenmab A/SLTM Jun 2026$788.1M USD—-43.9%19.1%
TGTXTG Therapeutics, Inc.LTM Sep 2026$106.06M USD-76.3%—11.8%
CGENCompugen Ltd.LTM Mar 2026$34.86M USD+346.4%—48.0%
IMCRImmunocore Holdings plcLTM Mar 2026-$18.82M USD+13.0%—4.9%
MGNXMacroGenics, Inc.LTM Mar 2026-$70.36M USD-26.1%—44.8%
XNCRXencor, Inc.LTM Jun 2026-$163.33M USD+8.8%—155.6%
IMTXImmatics N.V.LTM Mar 2026-€214.41M EUR-893.4%—574.9%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$220.54M USD+44.5%—58.2%
IBRXImmunityBio, Inc.LTM Sep 2026-$1.11B USD-218.3%—607.8%
BNTXBioNTech SELTM Jun 2026-€1.69B EUR-390.8%—64.0%
Peer median (excluding BNTX) —+8.8%+5.9%46.4%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.98B17.31B3.82B2.75B2.76B
Cost of Revenue2.91B3B599.8M541.3M616.47M
Gross Profit16.07B14.32B3.22B2.21B2.14B
Gross Margin84.7%82.7%84.3%80.3%77.6%
Research & Development949.2M1.54B1.78B2.25B2.02B
Selling, General & Admin327.2M541.2M557.7M599M698.2M
Operating Expenses781.4M1.67B2.53B3.52B2.76B
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
EBITDA15B13.1B1.38B(367.1M)(628M)
EBITDA Margin79.1%75.7%36.1%-13.3%-22.8%
Operating Income15.28B12.64B690.4M(1.31B)(623.87M)
Operating Margin80.5%73.0%18.1%-47.8%-22.6%
Interest Income1.56M47.37M351.31M0252.24M
Interest Expense5.63M15.82M7.76M13.16M13.64M
Other Income / Expenses(237.4M)311.4M495.7M636.6M(385.46M)
Income Before Tax15.05B12.95B1.19B(677.7M)(1.01B)
Pre-Tax Margin79.3%74.8%31.1%-24.6%-36.6%
Income Tax Expense4.75B3.52B255.8M(12.4M)81.93M
Net Income10.29B9.43B930.3M(665.3M)(1.09B)
Net Margin54.2%54.5%24.4%-24.2%-39.6%
EPS (Basic)43.8738.083.87(2.77)(4.51)
EPS (Diluted)41.2137.093.83(2.77)(4.51)
Weighted Avg Shares244M243.3M240.6M240.4M241.7M
Weighted Avg Shares (Diluted)259.7M249.8M242.7M240.4M241.7M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.